Cytokine profile in psoriatic arthritis: search for relationships with inflammation and blood rheological properties

Objective. To estimate the serum levels of interleukins (IL) 6 and 10, tumor necrosis factor-α (TNF-α) and vascular endothelial growth factor (VEGF) in patients with psoriatic arthritis (PSA) and their relationship with the clinical and laboratory parameters of inflammation and with erythrocyte aggregation (EA).
Material and methods. The authors measured the serum levels of C-reactive protein (CRP) by immunonephelometry (BN, ProSPEC, Siemens) and those of TNF-α, IL-6 and IL-10, and VEGF by X-MAP technology using a BioPlex-200 system (Panel Human 27-Plex Bio-Rad, USA) in 80 patients with PSA [45 women and 35 men; mean age 41.7±10.5 years, mean duration of PSA and psoriasis was 5.0 (2.0; 12,5) and 15 (4; 26) years, respectively; DAS 3.9 (3.09; 5.16)]. The blood samples from 16 healthy donors matched to the examinees for gender and age served as a control. The parameters of EA [Т1(с); Кt (arb. units); β (с-1), I2,5 (%)] were estimated, by recording the rate of back light scattering. The median (Me) and interquartile range [Q25; Q75], and mean and standard deviations (M±σ) were calculated; the indicators were compared by the Mann-Whitney test and Student's t test. Correlation analysis was made using the Spearman rank correlation coefficient (R); p < 0.05 was considered statistically significant.
Results. There were significantly higher serum levels of IL-6 and IL-10, TNF-α, and VEGF in patients with PSA than in the controls, and impaired blood rheological properties. There were significant correlations of the level of most cytokines (IL-6 and IL-10, VEGF) with both the values of the clinical and laboratory activity of PSA (self-rated pain, the number of swollen and tender joints, a physician's assessment of disease activity, DAS, erythrocyte sedimentation rate, and fibrinogen) and most parameters of EA (Т1, Kt и I2.5). No significant relationships were found between VEGF and CRP.
Conclusion. The enhanced clinical and laboratory activity of PSA is attended by the systemic activation of immunological mediators of inflammation and neoangiogenesis and by impaired blood rheological properties, which supports the interaction of these factors in the immunopathogenesis of the diseases.

psoriatic arthritis, erythrocyte aggregation, interleukins 6 and 10, tumor necrosis factor-a, vascular endothelial growth factor

1. <div><p>Veale D., Ritchlin С., FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005; 65(2): 26-9.</p><p>Mease P.I., Antoni C.E. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005; 64(2): 78-82.</p><p>Ritchlin C., Haas-Smith S.A., Hicks D. et al. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998; 25: 1544-52.</p><p>Kane D., Gogarty M., O'Leary J. et al. Reduction of synovial subblining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthr Rheum 2004; 50: 3286-95.</p><p>Danning C., Illei G., Hitchon C. et al. Macrophage-derived cytokine and nuclear factor kappa Bp65 expression in syraavial membrane and skin of patients with psoriatic arthritis. Arthr Rheum 2000; 43: 1244-56.</p><p>Ohta Y., Katayama I., Funato T. et al. In situ expression of messenger RNA of interleukin-1 and interleukin-6 in psoriasis: interleukin-6 involved in formation of psoriatic lesions. Arch Dermatol Researh 1991; 283(6): 351-6.</p><p>Veale D., Yanni G., Rogers S. et al. Reduced synovial membrane ELAM-1 expression, macrophage numbers and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthr Rheum 1993; 36: 893-900.</p><p>Assadulah K., Sabat R., Friedrich M. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy 2004; 3(2): 185-92.</p><p>Spadaro A., Taccari E., Riccieri V. et al. Interleukin-6 and soluble Interleukin-2- receptor in psoriatic arthritis: correlations with clinical and laboratory parameters. Clin Exp Rheumatol 1996; 14(4): 413-6.</p><p>Drourt M., Saas P., Billot M. et al. High serum vascular endothelial growth factor correlates with disease activity of spondlarthropathies. Clin Exp Immunol 2003; 132(1): 158-62.</p><p>Taylor W., Gladman D., Helliwell P. et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthr Rheum 2006; 54: 2665-73.</p><p>Gladman D., Helliwell P., Mease P. еt al. Assessment of patients with psoriatic arthritis. Arthr Rheum 2004; 50(1): 24-35.</p><p>Firsov N.N., Bjelle A., Korotaeva T.V. et al. Clinical application of measurement of spontaneous erythrocyte aggregation and disaggregation. Clin Hemorheol Microcirc 1998; 18: 87-97.</p><p>Ritchlin C. Psoriatic disease - from skin to bone. Nat Clin Pract Rheumatol 2007; 12(3): 698-706.</p><p>Peters R. Vascular endothelial growth factor and the angiopoietins. Working together to build a better blood vessel. Circulation Res 1998; 83: 342-3.</p><p>Fearon U., Reece R.J., Blythe D. et al. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implication for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann N Y Acad Sci 1999; 872: 619-21.</p><p>Creamer D.J., Jaggar R., Allen M. et al. Overexpression of the angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase in psoriatic epidermis. Br J Dermatol 1997; 137: 851-5.</p><p>Partsch G., Sreiner G., Leeb B. et al. Highly increased levels of tumor necrosis factor alpha and other cytokines in psoriatic arthritis. J Rheum 1997; 24: 518-23.</p><p>Canete J., Pablos J., Sanmarti R. et al. Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthr Rheum 2004; 50: 1636-41.</p><p>Drourt M., Saas P., Billot M. et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol 2003; 132(1): 158-62.</p><p>Veale D., FitzGerald O. Psoriatic arthritis. Best Pract Res Clin Rheumatol 2002; 16(4): 523-35.</p><p>McInnes I. Cytokine targeting in psoriasis and psoriatic arthritis: beyond TNFalpha. Ernst Shering Res Found Workshop 2006; 56: 29-44.</p><p>Fraser A.D., van Kuijk A.W., Westhoven R. et al. A randomized, double blind, placebo controlled, multicenter trial of combination therapy with methotrexate plus cyclosporine in patients with active psoriatic arthritis. Ann Rheum Dis 2005; 64: 859-64.</p><p>Goedkoop A.Y., Kraan M.C., Picavet D.I. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low infliximab therapy in combination with stable methotrexate therapy. Arthr Res Ther 2004; 6: 326-34.</p><p>Bognartz T., Coras B., Vogt T. et al. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatol (Oxford) 2005; 44: 126-9.</p><p>Lacraz S., Nicod L., Chicheportiche R. et al. IL-10 inhibitis metalloproteinase and stimulates TIMP-1 production in human monocuclear phagocytes. J Clin Invest 1995; 96: 2304-8.</p><p>Asadullah K., Friedrich M., Hannaken S. et al. Effects of systemic interleukin-10 therapy on psoriatic skin lesions: histological, immunohistological and molecularbiological findings. J Invest Dermatol 2001; 116: 721-7.</p><p>McInnes I., Illei G., Carol L. et al. IL- 10 improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001; 167: 4075-82.</p><p>Alenius G.M., Eriksson C., Rantapaa Dahlqvist S. Interleukin-6 and soluble Interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis. Clin Exp Rheumatol 2009; 27(1): 120-3.</p><p>Коротаева Т. В., Логинова Е. Ю., Новикова Д. С. и др. Реологические свойства крови при псориатическом артрите: связь с воспалением и кардиоваскулярным риском. Науч.-практич. ревматол. 2009; 5: 13-7.</p><p>Baskurt O.K., Uyuklu M., Ulker P. et al. Comparison of three instruments for measuring red blood cell aggregation. Clin Hemorheol Microcirc 2009; 43(4): 283-98.</p><p>Herrmann J., Lerman L., Mukhopadhyay D. et al. Angiogenesis in Atherogenesis. Arterioscl Thromb Vasc Biol 2006; 26: 1948-57.</p><p>Feinstein S. Contrast Ultrasound Imaging of the Carotid Artery Vasa Vasorum and Atherosclerotic Plaque Neovascularization. J Am Col Card 2006; 48: 236-43.</p><p>Leong T., Fearon U., Veale D. Angiogenesis in psoriasis and psoriatic arthritis: clues to disease pathogenesis. Curr Rheum Rep 2005; 7(4): 325-9.</p><p>Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль: Верхняя Волга, 1999; 616 с.</p></div><br />